Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASH 2017

CLL

View all
3:20
CLL updates from ASH 2017
Jacqueline Barrientos • 9 Dec 2017
2:04
MURANO trial: revolutionizing the standard of care for relapsed CLL patients
Stephan Stilgenbauer • 11 Dec 2017

MM

View all
4:48
Curative strategy for smoldering multiple myeloma: GEM-CESAR
Maria Victoria-Mateos • 9 Dec 2017
2:45
MRD-guided high-dose carfilzomib treatment for multiple myeloma
Ola Landgren • 9 Dec 2017

AML

View all
2:25
Update on immunotherapy trials for AML from ASH 2017: bispecific DARTs, CAR T-cells and ADCs
Marina Konopleva • 9 Dec 2017
3:08
AML highlights from ASH 2017
Charles Craddock • 9 Dec 2017

Lymphoma

View all
0:46
Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells
Nirali Shah • 9 Dec 2017
1:44
Treating lymphoma beyond progression
Graham Collins • 9 Dec 2017

ALL

View all
2:13
Elderly ALL advances: inotuzumab ozogamicin plus mini-hyper-CVD
Susan O’Brien • 9 Dec 2017
1:21
Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status
Nirali Shah • 9 Dec 2017
The content of VJHemOnc is intended for healthcare professionals